

BIBLIOGRAPHY

1. AARP Research/Survey on prescription drug issues and usage among Americans aged 50 & older. <http://research.aarp.org/health/summary.html>
2. Adams Chris, Financial Express, June, 25, 2002.
3. Agenda Note, IDMA Bulletin, XXXIII (20), 31st May, 2002.
4. Ahmed S.R., Crackdown on misleading drug promotion, Lancet, (1991), 338.
5. American Pharmaceutical Companies, Camtech www.camtech.net.au/malam
6. Anadaleeb S.S., Tallman R.F., Health Mark Q, 1996, 13(4)
7. Andaleeb Syed Saad and Tallman Robert F., Healthcare management review, 1995, 20(3).
8. Annual Reports 2001-02, The Medical Council of India, www.mci.org
9. Armstrong David and Reyburn Hugh, British Medical Journal, (1996) 312.
10. Ayurvedno Itihas, 1st edition, (1968) by Pdt. Hemraj Sharma, Translated by Shri G.M. Shastri.
11. Azeem Majid et al, What can PACT tell us about prescribing in general practice, British Medical Journal, vol. 14, No.1, Mar., 1998
12. Bartel Rebecca, rbartel@alphalink.com.au
13. Bavasso R.A., CEO, Pharmedica Communications, Inc. richieb@pharmedica.com
14. Becel et al and Prescrire editorial board, La revue Prescrire, vol4, no.18.
15. Bell R.A., Kravitz R.L., Wilkes M.S., Journal of Internal Medicine, 1999, Nov; 14(11)
16. Bell R.A., Wilkes M.S., Kravitz R.L., Journal Fam Pract, 1999, 48(6).
17. Beri G.C. Marketing Research, (1993), second edition.
18. Bhatt Arun D, "Drug Promotion and Doctors: A Changing Relationship" The Journal of General medicine, April-June 1996 vol.8, No.3.
19. Big Spenders, A& M 15th March, 2000.
20. Bricker E.M., Industrial marketing and medical ethics, New England Journal of Medicine, 1989, 230.
21. Britten Nicky et al, Continued prescribing of inappropriate drugs in general practice, Journal of Clinical Pharmacy and Therapeutics, 1995, 20.
22. Britten Nicky, British Medical Journal, vol. 310, April, 1999.
23. Britten Nicky, Obioha Ukoumunne, "The influence of patients' hopes of receiving a prescription on doctors' perceptions and the decision to prescribe". British Medical Journal, 1997, vol. 315.
24. Britten Nicky, Patient demand for prescriptions: a view from the other side, Family Practice, 1994:11.
25. Britten Nicky, Patients' ideas about medicines: a qualitative study in a general practice population, British Journal of General Practice, October, 1994.
26. Britten Nicky, Prescriber, Oct. 1994.
27. Butler Christopher C. et al., British Medical Journal, 1998, September, 317.
28. Canadian Medical Association, Physicians and the pharmaceutical industry (update 1998), www.cma.ca/inside/policybase/1998/06-19g.htm
29. Chambliss M. Lee, MD, Arch Fam Med, vol 3, December, 1994
30. Chemexcil Export Bulletin (2000) vol. XXXII No.3
31. Chiplunkar S.S., Express Pharma Pulse, vol. 8, No. 38, Aug., 2002.

32. Choudary Pavan kumar,(1997) The Rx factor, Response books.
33. Chrenn M.M., Llandefeld S, Murray T.H., Doctors, Drug Companies and gifts, JAMA, 1989, 262.
34. Cited Freudenheim Milt, in New York Times, November 17, 1998.
35. Cited in the editorial, Inpharm World Review, Issue 9, March 1, 2000, www.inpharm.com
36. CLSA, Indian Pharmaceutical Sector, No., 1998.
37. CMA policy, Physician and pharmaceutical industry update (1998), Approved by CMA board of Directors, June 19, 1998.
38. Cockburn Jill and Pit Sabrina, British Medical Journal, August 1997, 315.
39. Code of practice for the pharmaceutical industry, sixth edition, Jan., 1984
40. Couch James B., MD, Is prescription management keeping pace with the evolving need to demonstrate value, Drug Benefit Trends, 1998, 10(4)
41. Creyer Elizabeth H.& Hrsistodoulakis Ilias, Marketing Health Services, Summer, 1998.
42. Dasco Clifford & Rodning Charles, Editorial, A Physician/Medical Industrial Ethos, The American Journal of Medicine, December,1985, vol. 79, No.6.
43. David J. Luck & Ronald S. Rubin, Marketing Research, (1999) seventh edition, Prentice-Hall Publication.
44. Dilution of price controls has not raised R&D spending, Express Pharma Pulse, 14th September, 2000.
45. Dr. Gala Dhiren, Homœopathy for common-diseases (1995)-----
46. Dr. Nitya Nand, CDRI, Lucknow, Key note address, IDMA Bulletin XXXII(1) 7th Jan.2002.
47. Dr. Patel J.C., The Journal of General Medicine, Jan-march, 1996,vol.8 No.2,
48. Dr. Sen Gupta Amit , Should drug prices be controlled, The Economic Times, Tuesday 6 August, 2002.
49. Dr. Smarta, Revitalizing the Pharmaceutical Business,(1995)
50. Druid IT Management consultancy, Chemicals & Pharmaceuticals, ----- www.inpharm.com/reports/druidmedinfo.html.
51. Dubey Rajeev, Surender T, The great pumping up, Businessworld, 11th March, 2002
52. Eaton G, Parish P., Medical training and prescribing activity: Prescribing in General Practice, Journal of the Royal College of General Practitioner, 26 (Suppl 1)
53. Editorial, Stick to your system or suffer, MIMS INDIA, July, 1996
54. Ethical criteria for medicinal drug promotion, World Health Organization, Geneva, 1988
55. Experts debate the value of drug advertising, Reuters,www.foxnews.com/health/012799/drugads.sml
56. Fabro Dana, Senior Account Manager, Nethod LLC, Interactive services, danafabro@nethod-euro.com
57. Federation of Medical Representatives' Associations of India, official website www.fmrai.org
58. Frederick James & West Diane, Drug Stores News, New York, Dec. 17, 2001, 23(18)
59. Freudenheim Milt, The Media Business: Advertising, New York Times, November 17, 1998
60. Friedman M.L., J Hosp Mark, 1990, 4(2)

- 61 Gill P.S et al, Changing doctor's prescribing behaviour, Pharma World Science, Aug, 1999, 21(4).
- 62 Gill P.S., Dowell A.& Harris C.M., The effect of doctor ethnicity and country of qualification on prescribing patterns: an ecological study., Journal of Clinical Pharmacy and Therapeutics, 199, 24.
- 63 Gilzene Kerry, Will e-marketing strategies be successful in 2001?, World Pharmaceutical Developments, Dec., 2000.
64. Goldfinger Stephen E., Sounding Board, a matter of influence, The New England Journal of Medicine, May 1987, vol. 315
65. Goleman David, (1995) Emotional Intelligence, Bantam Books.
66. Goodman & Gilman's Pharmacological Basis of Therapeutics, eighth edition.
- 67 Greenberg Daniel S., Washington Perspective, The Lancet, Dec. 1990, vol. 336.
- 68 Gupta M P & Gupta S.P., Business Statistics, (1996)
69. Hennis Norma, Mnrk@AOL.COM
70. Himmel Wolfgang, Kochen Michael M., Letters, British Medical Journal, July, 1998, 317.
71. Hollon Matthew F. JAMA, vol. 281, No.4, January 27, 1999
72. Huston P., Medical Marketing and Media, 28, (March 1993).
73. India Infoline, pharmaceuticals-Generics, www.indiaonline.com/sect/gene/ch06.html
74. India Infoline, Pharmaceutical-Generics, The approval process, www.indiaonline.com/sect/gene/ch03.html
75. India infoline-Sector reports. www.indiaonline.com Page [sect/phfo/ch5h.html](http://www.indiaonline.com/sect/phfo/ch5h.html)
76. Institute of public opinion, vol. XLVI No.2, November,2000.
77. Jain Kalpana, Sunday Times of India, 2nd June, 2002
78. Johnson Richard & Wichern Dean, Applied multivariate statistical analysis, (2001), Third edition
79. Jones I., Britten N, British Journal of General Practice, 1998 Jan:48 (426)
80. Jorm Anthony F., letters, Medical Journal of Australia, 1996, vol. 166.
81. Kamath Gauri and Gothivarekar Nutan, The Economic Times, 20th December, 2001.
82. Kangis P, Van Der Geer L, Pharmaco-economic information and its effect on prescriptions, J Manag Med, 1996, 10(5)
83. Kelley H.H., "The two functions of reference groups", 2nd edition
84. Kelley Samuel, (2000) Kelley School of Business, pharma-mkting@virsci.com, 29.02.00
85. Kelley Samuel, pharma-marketing@virsci.com July, 10, 2000
86. Krishnaswamy K., Radhaiah G , A drug survey, Eur J Clin Pharmacol, 1985, 29(3)
87. Kshirsagar M.J., et al, Bull World Health Organ, 1998, 76(3)
88. Kunin Calvin M., Clinical investigators and the pharmaceutical industry, Annals of Internal Medicine, 1978, 89(2)
89. Kush Zan, pharma-mkting@virsci.com, July, 09, 2000
90. Langreth Robert, Drug Marketing Drives Many clinical Trials, The Wall Street Journal, Nov. 16, 1998.
91. Leslie Harris, creation@ALLTEL.net,

92. Levin Richard I & Rubin David S (2002) Statistics for management, seventh edition.
93. Levy R., The role and value of pharmaceutical marketing, Arch Fam Med, 1994, Apr,3 (4) p.327-32
94. Lexchin J., Canadian Family Physician, May 1997, 43.
95. Lizamore Dave, dlizamor@medic.up.ac.za, Pharma-marketing internet interactive group
96. Mack John, pharma-mkting@virsci.com, February 28, 2002.
97. Madhavan S. et al, Journal of clinical pharmacy and therapeutics(1997) 22.
98. Majumdar Ramanuj, Marketing research, text, applications and case studies, (1991)
99. Manfield P.R., How does pharmaceutical company promotion affect prescribing, www.who.int/dap-icium/posters/4p7_fintext.html.
100. Mascarenhas Anuradha, Indian Express, 30th Nov , 2001
101. McCormick Douglas, Physician Verification Services Inc , doug.mccormick@verifies.com
102. Mehta P.J., Do they need prescriptions?, Medicine update, Oct., 1996
103. Merton R.K., "Social theory and social structure", Glencoe, IL, Free Press, 1957
104. Mick. T, "Pharmaceutical Funding and Medical Students", The Journal of the American Medical Association, 265(1991).
105. Mintzes Barbara, Blurring the Boundaries, New Trends in Drug-Promotion, HAI-Europe, 1998, www.haiweb.org/pubs/blurring/blurring_ch2.html.
106. Myers Greerm,, greerm@televox.com
107. Office visits result in prescription for drugs, Drug Benefit Trends, 1998, 10(9).
108. ORG-MARG, Milestones: Pharmaceutical client conference , April,1999 publication.
109. Ostergaard Daniel J., editorial, The Journal of Family Practice, 1992, vol 34, No.1.
110. Pati Debashish, (2002), Marketing Research, Universities Press (India) Pvt. Ltd.
111. Peranio Steve, Deardorff Frank, Physicians' Online Network, February 24, 1998. www.po.com
112. Perry Robert F., MD, JAMA, October 25, 1995, vol. 274, No. 16
113. Peyrot M. et al. Marketing Health Services, 1998, Summer, 18(2)
114. Prasad H.A.C., The new patents regime: implications for India's pharmaceutical sector, Productivity, vol. 3, No.1, April-June, 1997
115. Ragg Mark, Capsule or pill, don't swallow it whole, Weekend Australian, March 27-28, 1999
116. Raj Mala, Unethical pharmaceutical marketing, Express pharma pulse, July 5, 2001
117. Ramachandran R , Unhealthy policy, Frontline, March, 2002, p.80-83
118. Ramsden James D., British Medical Journal, March 1998, 316.
119. Randall Terryl, JAMA, Jan. 1991, vol. 265, No.4.
120. Rapport David, MD, North York, Ontario, Canada, Journal of Canadian Medical Association, Jan, 1995, 152(1).
121. Reach of Allopathic medicines, Monthly public opinion surveys of the Indian institute of opinion poll
122. Readers Report, Business week, February 7,2000.

123. Redelmeier DA & Shafir E, Medical decision making in situations that offer multiple alternatives, JAMA, 1995, 272
124. Remington's Practice of Pharmacy, 9th edition.
125. Reuters, January 27, 1999
126. Roberts Doug, pharma-mkting@virsci.com, January 3, 2001
127. Robinson Jeffrey, Prescription Games, Simon & Schuster U.K. Ltd.,(2001).
128. Schectman J.M. et al, Med Care, 1995, 33(2)
129. Schwartz Janet et al, Are more options always better?, Medical Decision Making, 1999, 19.
130. Schwartz R.K., Soumerai S.B., Avorn j, Soc Sci. Med, 199, 28(6).
131. Shamsi Kamran, Kamran.shamsi@KBA.COM.AU, in a communication to pharma-marketing, a web group
132. Sharma K.K., Statistics in management studies, (1999), second edition.
133. Sharma Y, Das D.G., A critical review of prescriptions in internal medicine, J Assoc Physicians India, 1992, June, 40(6)
134. Shelton Graham, World Pharmaceutical Development, Dec, 2001
135. Shoemaker Adam, ashoemaker@MIGKAP.COM
136. Shri Gandhi N.I., Drug Industry Overview, IDMA BULLETIN XXXII(5) 7th Feb,2002.
137. Sigmand Norman B , Effective communication for pharmacist and other healthcare professionals, (1996)
138. Smith Richards, Doctors and the drug industry: too close for comfort, British Medical Journal, 1986, Oct , vol.293
139. Sonnenreich Peter, pharma-mkting@virsci.com February 28, 2002.
140. SPSS FAQ: What does Cronbach's alpha mean, UCLA Academic Technology Services.www.ats.ucla.edu/stat/spss/modules/default.htm
141. Strategic Businesswire, Mumbai, Pharma Business, May 26, 2000.
142. Subba Rao S.V.R, Handbook of Pharmaceutical marketing in India, (1993)
143. Swanson Rick W., Hall William G. & Penny A. Jennet, Academic Medicine, vol.69 (2) February, 1994.
144. Swift Louise, Quantitative methods for business, management & finance, (2001)
145. Syed Umar, Management consultant, PWC, umar.syed@PWCGLOBAL.COM
146. Syed Umar, pharma-marketing@virsci.com January 25, 2000
147. The Detroit News, May 24, 1996
148. Tuli,Varunesh, Chemical world, May 6, 2002.
149. Uzych Leo, "Physicians, Gifts and the Pharmaceutical Industry", Nebraska Medical Journal, September, 1991.
150. V. Rishi Kumar, The Internet is changing the healthcare industry dramatically, Business Line, 26th August 1999.
151. Virji Abbas and Britten Nicky, A study of the relationship between patients' attitudes and doctors' prescribing, Family Practice, 1991, vol.4.
152. Walsh John, communication to pharma-marketing@virsci.com, Feb. 2000.
153. Waud G.R., Pharmaceutical Promotions- a free lunch?, New England Journal of medicine, 1992, 327.
154. Wellbery Caroline, M.D., American Family physician, vol.55, No.5, April 1997,
155. Whyte J. Direct Consumer Advertising of Prescription Drugs, JAMA, 1993, 269.

- 156 Wilkin D, Hallam L, Leavey R, Metcalfe D, 1987, anatomy of Urban General Practice, London, Tavistock
- 157 www.eyeforpharma.com, Pharma-Marketing News, vol 1, Number 3, March 2002
- 158 Wysong Pipa, The Medical post, September 8, 1998
- 159 Zuger Abigail, New York Times, January 11, 1999